CROI 2015 Program and Abstracts

Oral Sessions

649 Successful HCV Treatment With Direct Acting Antivirals in HIV/HCV Patients Jennifer L. Grant 1 ;Valentina Stosor 1 ; Frank J. Palella 1 ; Richard M. Green 1 ; GuajiraThomas 1 ; DonnaV. McGregor 1 ; Milena M. McLaughlin 2 ; Sudhir Penugonda 1 ; Michael Angarone 1 ; Claudia Hawkins 1 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2 Midwestern University, Chicago, IL, US 645 Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice Jody Gilmore 1 ; Kenneth Lynn 1 ; Delisha Breen 1 ; StaceyTrooskin 2 ; Jihad Slim 3 ; Nancy Scangarello 3 ; Alvin Kingcade 4 ; Katie Hunyh 4 ;Vincent Lo Re 1 ; Jay R. Kostman 1 1 Perelman School of Medicine, Philadelphia, PA, US; 2 Drexel University College of Medicine, Philadelphia, PA, US; 3 St Michael’s Medical Center, Newark, NJ, US; 4 Philadelphia Health Management Corporation, Philadelphia, PA, US 648 Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious AEs Ponni V. Perumalswami 1 ; Kian Bichoupan 1 ; Lawrence Ku 1 ; Neal M. Patel 1 ; Rachana Yalamanchili 1 ;Thomas Schiano 1 ; MarkWoodward 2 ; Douglas Dieterich 1 ; Andrea D. Branch 1 1 Icahn School of Medicine at Mount Sinai, New York, NY, US; 2 George Institute for Health at the University of Oxford, Oxford, United Kingdom 651 Majority of HIV/HCV Patients Need to Switch ART to Accommodate Simeprevir Rebecca Cope 1 ; Aaron Pickering 2 ;Thomas Glowa 1 ; Samantha Faulds 1 ; PeterVeldkamp 1 ; Ramakrishna Prasad 1 1 University of Pittsburgh, Pittsburgh, PA, US; 2 University of Maryland, Glen Burnie, MD, US 644 Sofosubuvir, Simeprevir, +/- Ribavirin in HCV Protease Inhibitor- Experienced Patients Kristen M. Marks ; Ethan M.Weinberg; Sonal Kumar; Carrie Down;Ype P. de Jong; Leah A. Burke; Mary C. Olson; Ira M. Jacobson Weill Cornell Medical College, New York, NY, US Session TD-P Themed Discussion Room 6E 1:30 pm– 2:30 pm Cardiovascular Risk Prediction: CanWe Do Better? Themed Discussion Leader Nina Friis-Moller , Odense University Hospital, Odense, Denmark 746 Cumulative HIV Care Measures Highly AssociatedWith Acute Myocardial Infarction Jorge L. Salinas 1 ; ChristopherT. Rentsch 2 ;Vincent C. Marconi 1 ; JanetTate 3 ; Adeel A. Butt 4 ; Matthew S. Freiberg 4 ; Matthew B. Goetz 5 ; Maria Rodriguez-Barradas 6 ; Amy Justice 3 ; David Rimland 1 1 Emory University, Atlanta, GA, US; 2 Atlanta VA Hospital, Decatur, GA, US; 3 Yale University, New Haven, CT, US; 4 University of Pittsburgh, Pittsburgh, PA, US; 5 David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 6 Baylor College of Medicine, Houston, TX, US 747 Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS) Angela M.Thompson-Paul 1 ; Kenneth A. Lichtenstein 2 ; Carl Armon 3 ; Kate Buchacz 1 ; Rachel Debes 3 ; Joan S. Chmiel 4 ; Frank J. Palella 4 ; Stanley C.Wei 1 ; Jacek Skarbinski 1 ; JohnT. Brooks 1 1 US Centers for Disease Control and Prevention, Atlanta, GA, US; 2 National Jewish Health, Denver, CO, US; 3 Cerner Corporation, Vienna, VA, US; 4 Northwestern University, Feinberg School of Medicine, Chicago, IL, US 748 Incidence and Risk of Myocardial Infarction (MI) by Type in the NA- ACCORD Daniel R. Drozd 1 ; Mari M. Kitahata 1 ; Keri N. Althoff 2 ; Jinbing Zhang 2 ; Susan R. Heckbert 1 ; Matthew J. Budoff 3 ; Frank J. Palella 4 ; Daniel B. Klein 5 ; Richard D. Moore 6 ; Heidi M. Crane 1 1 University of Washington, Seattle, WA, US; 2 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3 University of California Los Angeles, Los Angeles, CA, US; 4 Northwestern University, Chicago, IL, US; 5 Kaiser Permanente Northern California, Hayward, CA, US; 6 Johns Hopkins University, Baltimore, MD, US

750 HIV-Infected Veterans and the New ACC/AHA Cholesterol Guidelines: Got Statins? Meredith E. Clement 1 ; Lawrence Park 1 ; Ann Marie Navar-Boggan 1 ; Nwora L. Okeke 1 ; Michael Pencina 1 ; Pamela Douglas 1 ; Susanna Naggie 1 1 Duke University, Durham, NC, US; 2 Duke University, Durham, NC, US; 3 Duke University, Durham, NC, US 751 Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV- Infected Patients Susan Regan 2 ; James B. Meigs 2 ; Joseph Massaro 3 ; Ralph B. D’Agostino 3 ; Steven Grinspoon 2 ; Virginia A. Triant 2 1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3 Boston University, Boston, MA, US; 4 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US 1:30 pm– 2:30 pm Keys to the Kingdom: Viral Suppression in Pregnant and PostpartumWomen Themed Discussion Leader Laurent Mandelbrot , Hopital Louis Mourier, Colombes, France 863 Specific Effects of ZDV, 3TC and LPV/r on HIV-1 RNA Viral Load During Pregnancy Patumrat Sripan 1 ; Sophie Le Coeur 5 ; Lily Ingsrisawang 2 ;Tim R. Cressey 3 ; Jean-Marc Tréluyer 6 ; Naïm Bouazza 4 ; Frantz Foissac 4 ; Gonzague Jourdain 3 ; Marc G. Lallemant 3 ; Saïk Urien 7 1 ED420, University of Paris Sud 11, Paris Descartes, Paris, France/PHPT-IRD UMI 174, Chiang Mai, Thailand/Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 2 Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 3 PHPT-IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University/ Harvard School of Public Health, Chiang Mai, Thailand; 4 EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Paris, France; 5 Institut d’Etudes Démographiques, Institut de Recherche Pour le Développement (UMR 196 CEPED), Paris, France/Harvard School of Public Health, Boston, MA, USA/Faculty of Associated Medical Science, Chiang Mai University, Chiang Mai, Thailand; 6 EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Service de Pharmacologie Clinique, AP-HP, Groupe Hospitalier Paris Centre, CIC-0901 Inserm, Cochin- Necker, Paris, France; 7 EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, CIC-0901 Inserm, Cochin-Necker, Paris, France 864 Viral Suppression After Antiretroviral Therapy Initiation in Pregnancy in South Africa Landon Myer 1 ;Tamsin Phillips 1 ; Nei-Yuan Hsiao 2 ; Allison Zerbe 3 ; Jo Ramjith 1 ; Linda-Gail Bekker 1 ; James A. McIntyre 4 ; Elaine J. Abrams 3 1 University of Cape Town, Cape Town, South Africa; 2 National Health Laboratory Services/ University of Cape Town, Cape Town, South Africa; 3 ICAP at Columbia University, New York, NY, US; 4 Anova Health Institute, Johannesburg, South Africa 865 Maternal Viral Load in the Context of PMTCT B+Within the Kabeho Study in Kigali Emily A. Bobrow 1 ; Placidie Mugwaneza 2 ; Gilles F. Ndayisaba 3 ; Dieudonne Ndatimana 3 ; Michelle Gill 1 ; Heather J. Hoffman 4 ; Cyprien Baribwira 5 ; Laura Guay 1 ; Anita Asiimwe 6 On behalf of the Kabeho StudyTeam 1 Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, US; 2 Ministry of Health, Kigali, Rwanda; 3 Elizabeth Glaser Pediatric AIDS Foundation, Kigali, Rwanda; 4 George Washington University Milken Institute School of Public Health, Washington, DC, US; 5 University of Maryland, School of Medicine, Kigali, Rwanda; 6 Rwanda University Teaching Hospitals, Kigali, Rwanda 866 ART Response Among Pregnant and PostpartumWomenWith Acute Versus Chronic HIV-1 Alison L. Drake 1 ; John Kinuthia 2 ; Daniel Matemo 2 ; Barbra Richardson 1 ; Michael Chung 1 ; James N. Kiarie 2 ; Sandy Emery 3 ; Julie M. Overbaugh 3 ; Grace John-Stewart 1 1 University of Washington, Seattle, WA, US; 2 University of Nairobi, Nairobi, Kenya; 3 Fred Hutchinson Cancer Research Center, Seattle, WA, US Session TD-T Themed Discussion Room 6D

Thursday, February 26, 2015 • Oral Sessions

19

CROI 2015